10:00 AM
to
16:00 PM
10:00 AM
to
16:00 PM
10:00 AM
to
16:00 PM
10:00 AM
to
16:00 PM
10:00 AM
to
16:00 PM
10:00 AM
to
16:00 PM
Dr. Sarita Shrivastva is an experienced medical and hemato oncologist with 10 years of experience in cancer diagnosis and treatment.
She specializes in managing various cancers with a patient-focused approach, ensuring personalized and advanced care for each individual.
She is practicing at Medicover Hospitals, Hyderabad, providing advanced cancer care with a patient-centric approach.
Her expertise includes treating brain tumors, head and neck cancers, thyroid cancers, lung cancer, breast cancer, gastrointestinal cancers, and gynecologic cancers.
Additionally, she is interested in genetic counseling and managing hereditary cancers, helping patients understand and mitigate their cancer risks.
Dr. Sarita Shrivastva has an impressive academic background. She completed her DM in Medical Oncology from Nizam's Institute of Medical Sciences (NIMS), Hyderabad, and an MD in Radiation Oncology.
She has further enhanced her expertise with MRCP UK SCE in Medical Oncology, making her a globally recognized expert.
Her contributions to oncology extend beyond clinical practice.
She has presented research papers at international conferences like ESMO (European Society for Medical Oncology) and ISMPOCON, focusing on cutting-edge advancements in cancer treatment.
She has also received multiple awards for her excellence in oncology, including three national-level ICON quiz championships and the Best Poster Presentation at ISMPOCON 2018.
As a compassionate oncologist, Dr. Sarita Shrivastva prioritizes personalized treatment plans tailored to each patient's condition. She stays at the forefront of oncology research to incorporate the latest chemotherapy, immunotherapy, and targeted therapy advancements into her practice.
Why Choose Dr. Sarita Shrivastva?
✔ Over a decade of experience in oncology
✔ Expert in treating a wide range of cancers
✔ Recognized researcher and award-winning oncologist
✔ Personalized cancer treatment plans
✔ Advanced expertise in genetic counseling and hereditary cancers
Consultant, Medical Oncologist and Hemato-Oncologist
MBBS: Dr. NTR University of Health Sciences, Andhra Pradesh, 2010.
MD (Radiation Oncology): MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, 2009.
DM (Medical Oncology): Nizam's Institute of Medical Sciences (NIMS), Hyderabad.
MRCP UK SCE (Medical Oncology): Membership of the Royal Colleges of Physicians, United Kingdom.
Brain tumors.
Head and neck cancers.
Thyroid cancers.
Lung cancer.
Breast cancer.
Gastrointestinal cancers.
Gynecologic cancers.
Genetic counseling and management of hereditary cancers.
Winner of the 42nd National Level ICON Quiz, March 2020, Hyderabad.
Winner of the 41st National Level ICON Quiz, September 2019, Ahmedabad.
Winner of the 40th National Level ICON Quiz, March 2019, Kolkata.
Recipient of the Best Poster Presentation at ISMPOCON 2018, Jaipur.
Memberships:
Member of the European Society of Medical Oncology (ESMO).
Member of the Association of Radiation Oncologists of India (AROI).
Dr. Sarita Shrivastva has an impressive portfolio of six research papers presented and published at prestigious national and international conferences. Her contributions to oncology research include:
ESMO Asia, Singapore (2019): Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single-center experience.
ESMO Breast Cancer Annual Congress, Berlin (2019): Trastuzumab related cardiotoxicity in non-metastatic breast cancer: A real-world scenario.
40th ICON Conference, Kolkata (2019): Clinico-pathological profile, treatment, and outcomes of metastatic gastric cancer: An institutional experience.
ISMPOCON, Jaipur (2018): Anaplastic lymphoma kinase positive advanced NSCLC: An institutional experience.
Asian Pacific Journal of Health Sciences (2016): Comparison of weekly cisplatin with three-weekly cisplatin with concurrent radiation in locally advanced head and neck cancers.
South Asian Journal of Cancer (Accepted for Publication): Trastuzumab related cardiotoxicity in adjuvant setting: A real-world scenario.